Key Insights

Highlights

Success Rate

92% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

7.7%

2 terminated out of 26 trials

Success Rate

91.7%

+5.2% vs benchmark

Late-Stage Pipeline

19%

5 trials in Phase 3/4

Results Transparency

14%

3 of 22 completed with results

Key Signals

3 with results92% success

Data Visualizations

Phase Distribution

12Total
Not Applicable (2)
P 1 (3)
P 2 (2)
P 3 (4)
P 4 (1)

Trial Status

Completed22
Terminated2
Enrolling By Invitation1
Unknown1

Trial Success Rate

91.7%

Benchmark: 86.5%

Based on 22 completed trials

Clinical Trials (26)

Showing 20 of 20 trials
NCT02613403Phase 2Terminated

Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)

NCT05492565Enrolling By Invitation

Seville Cohort of People at Substantial Risk for HIV Infection on Pre-exposure Prophylaxis

NCT03776760Unknown

Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination

NCT03410953Phase 4Completed

Vaccination Adjuved Against Hepatitis B in SNS Workers Typed as no Responders to Conventional Vaccines

NCT00342186CompletedPrimary

Genes Involved in Resistance or Susceptibility to Hepatitis B Virus

NCT00913757Completed

A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area

NCT00005304Completed

Delta Hepatitis and Liver Disease in Hemophiliacs

NCT00230854Phase 1Completed

Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated Interferon and Ribavirin

NCT00005309Completed

Prospective Study of HIV Infection in Hemophiliacs

NCT01532973Phase 1CompletedPrimary

Safety, Pharmacokinetics and Pharmacodynamics of Elbasvir (MK-8742) in Hepatitis C Infected Males (MK-8742-002)

NCT01804829Phase 3Completed

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.

NCT00007371Completed

Hepatitis C in Clinically Discordant Hemophilic Siblings

NCT00005305Completed

Hepatitis Delta Infections in Hemophiliacs

NCT00097006Completed

Retrovirus Epidemiology Donor Study-II (REDS-II)

NCT00005306CompletedPrimary

Natural History of Post-transfusion Non-A, Non-B Hepatitis

NCT00005339CompletedPrimary

Risk of Post Transfusion Hepatitis C Virus Infection

NCT00029406Completed

Transfusion Infections Pediatric Prospective Study (TRIPPS)

NCT00564811Not ApplicableCompleted

Effect of Agaricus Blazei (Murrill) ss. Heinemann (Sun Mushroom)

NCT00000580Phase 3Completed

Interruption of Maternal-to-Infant Transmission of Hepatitis B by Means of Hepatitis B Immune Globulin

NCT00000583Phase 3Completed

Hepatitis B Vaccine Clinical Trial

Scroll to load more

Research Network

Activity Timeline